Business
FDI Easing Not For Chinese firms; To Benefit Entities With Minority Chinese Holding: Report
Last Updated:
As per the amended press note 3, investors with non-controlling LBC beneficial ownership of up to 10 per cent shall be permitted under the automatic route.
The Union Cabinet on March 10 made changes in the press note 3 of 2020. Under the press note, investors from countries sharing land borders with India had to seek mandatory approval to invest in any sector.
Overseas companies having Chinese shareholding of up to 10 per cent will be eligible to invest in India under the automatic route across sectors; however, the relaxed FDI norms will not apply to entities registered in China/Hong Kong or other countries sharing land borders with India, a senior official said on Wednesday.
Earlier, foreign firms with shareholders from these land border nations owning even a single share had to seek mandatory approval to invest in India in any sector.
The Union Cabinet on March 10 made changes in the press note 3 of 2020 in this regard. Under the press note, investors from countries sharing land borders with India had to seek mandatory approval to invest in any sector.
“All the restrictions for investors from land bordering countries (LBCs) are still applicable. There is no relaxation so far as entities or investors in LBCs are concerned. This relaxation is only for entities in non-LBCs and having beneficial owners from LBCs below 10 per cent and non-controlling stake… so there are no relaxations so far as investments from LBCs are concerned,” Joint Secretary in the department for promotion of industry and internal trade (DPIIT) Jai Prakash Shivahare told reporters here.
He further explained that if a firm from a country sharing a land border with India provides technology and holds even one per cent stake, through which it may exercise some form of control, the investment will still require approval through the government route.
As per the amended press note, investors with non-controlling LBC beneficial ownership of up to 10 per cent shall be permitted under the automatic route as per the applicable sectoral caps, entry routes, and other conditions.
Such investments will be subject only to the reporting of relevant information or details by the investee entity to the DPIIT.
The government has, however, announced an expedited clearance to foreign direct investment (FDI) proposals of companies from China and other countries sharing land borders with India.
Proposals for LBC investments in specified sectors and activities of manufacturing in capital goods, electronic capital goods, electronic components, polysilicon and ingot-wafer, advance battery components, rare earth permanent magnets and rare earth processing shall be processed and decided within 60 days.
DPIIT Secretary Amardeep Singh Bhatia said that this list can be expanded or reduced by a committee of secretaries headed by the cabinet secretary.
At present, about 600 applications are under the press note 3.
When asked what would happen to those applications, the secretary said many would fall under either of the two categories – below the 10 per cent threshold and the expedited mechanism.
Those covered under the below-10 per cent limit can proceed with the investment after the notification is issued and subsequently file the required information, while those who want to come under the expedited mechanism can resubmit their applications.
A specific mechanism has been laid down for expedited approvals to ensure that the 60-day timeline is followed, as it would provide certainty to probable investors, Bhatia said.
“Now we are providing a non-PN3 route for those which are below the threshold of ownership and control…If a company from LBC wants to invest in India, in that case, the PN3 route will apply,” he said, adding that the concept of beneficial ownership (BO) is relevant for companies that are located outside the land border-sharing nations.
He added that companies like BlackRock were seeking the easing of the press note. The benefit of the expedited process can be availed by a company outside LBCs also.
“In the expedited process, some steps have been done away with…but broadly, as far as the security clearances are required, political clearance is required, that process will remain in place,” the secretary said.
He informed that a portal is being prepared so that applicants can file the information and go ahead with their investments.
For others, like in specified sectors, there is a separate provision in the portal that is being made so that they will get clearances within 60 days.
When asked about the criteria followed to identify the specified sectors, he said, in these areas, “we found that we need to increase manufacturing in India”.
“We need manufacturing to take place in India, whether it is a sewing machine or whether it is an Industry 4.0 machine which are assembling solar cells, or whether it is switchgear and so on. So, these are areas in which we feel there is a large scope of partnership, and joint ventures…But having said that, this is not a watertight compartment,” Bhatia said.
That is why the flexibility is there to add or subtract sectors.
The changes approved by the cabinet will be notified by the DPIIT and the Department of Economic Affairs. After that, it will come into effect.
“We will try to get it done as soon as possible,” he added.
(This story has not been edited by News18 staff and is published from a syndicated news agency feed – PTI)
March 11, 2026, 18:08 IST
Read More
Intellia Therapeutics, building exterior and company sign, Cambridge, Massachusetts, USA.
Spencer Grant | Universal Images Group | Getty Images
Intellia Therapeutics said its Crispr-based treatment for a rare swelling condition met its goals in a late-stage trial, marking a milestone for the field of gene editing and putting the company on track to seek approval from the U.S. Food and Drug Administration.
The company’s treatment uses Nobel Prize-winning technology Crispr to edit DNA and turn off the gene that controls production of a peptide that’s overactive in people with hereditary angioedema, causing them to experience potentially life-threatening swelling attacks. Intellia’s treatment is administered once through an hourslong infusion, making the edits directly in the liver.
Intellia said the one-time treatment reduced attacks by 87% compared with a placebo, meeting the study’s main goal. Six months after treatment, 62% of patients were free from attacks and weren’t using other therapies, Intellia said.
The company described the safety and tolerability of the treatment as “favorable,” reporting the most common side effects were infusion-related reactions, headaches and fatigue. Analysts were closely watching safety in the trial since a patient in a separate trial of a different treatment from Intellia died. That patient developed a liver injury and ultimately died from septic shock following an ulcer, according to the company.
“When you think about where we started with Crispr, just 12 years ago with some of the fundamental insights, I think there was a lot of talk about what might be possible, and we’ve had reports along the way in terms of milestones, but this is the first Phase 3 data in any indication with in vivo Crispr where you’re actually changing a gene that causes disease,” said Intellia CEO John Leonard.
The only FDA-approved Crispr-based medicine comes from Vertex Pharmaceuticals. Called Casgevy, the gene editing is done outside the body, or ex vivo. The process requires collecting a person’s blood cells, making the edits outside the body, then reinfusing them back into a patient. Intellia’s treatment, meanwhile, makes the edits inside the body, or in vivo.
Intellia said it has started a rolling application with the FDA and plans to complete the filing in the second half of this year. The company expects to launch the treatment in the U.S. in the first half of next year, if it’s approved.
If approved, Intellia’s treatment, lonvoguran ziclumeran, will compete with about a dozen other chronic drugs for HAE. Despite the allure of a one-time treatment, genetic medicines haven’t always been a commercial successes. BioMarin withdrew its gene therapy for Hemophilia A because of weak sales, for example.
Leonard said there are important differences between the two, like the fact that BioMarin’s therapy faced questions about how long the effects would last. In contrast, he said Intellia hasn’t seen a single case in almost six years where the effects diminished over time.
Despite the results, he’s reluctant to call Intellia’s treatment a functional cure.
“I think this is a tipping point for the disease and tipping point for Crispr-based in vivo therapy where you can make a change [and] it’s permanent,” Leonard said. “And, as far as we can tell, we don’t have a single patient in this program or other program where there’s been any waning of the effect of what we did to the gene or the effect of what we’ve seen with the clinical aspects of the disease itself. So it’s pretty exciting.”
Clarification: This story has been updated to clarify that a patient in a separate trial of a different treatment from Intellia developed acute liver injury and ultimately died from septic shock following an ulcer.
While many airlines say they are raising prices due to high fuel costs, József Váradi says European airlines are trying to boost demand
Source link
All of the chain’s standalone stores have stopped trading in the UK and Ireland.
Source link
King Charles and the Trumps unite at White House for a historic tea meeting
This M5 MacBook Air Discount Has Renewed My Faith in Cheap Laptops for 2026
Norway joins Type 26 Frigate Programme to boost NATO naval power
-
Sports1 week agoNCAA men’s gymnastics championship: All-time winners list
-
Sports1 week agoWWE WrestleMania 42 Night 2: Live match results and analysis
-
Politics7 days agoUK’s Starmer seeks to deflect blame over Mandelson appointment
-
Fashion1 week agoUK’s Sosandar returns to profitability amid robust FY26 performance
-
Entertainment1 week agoLee Anderson, Zarah Sultana kicked out of UK Parliament for calling PM ‘liar’
-
Business1 week agoHow Trump’s psychedelics executive order could unlock stalled cannabis reform
-
Business1 week agoNo fuel shortage: Govt assures 100% domestic LPG, PNG, CNG supply amid Hormuz energy crunch – The Times of India
-
Sports1 week agoQuetta Gladiators opt to bowl after winning toss against Peshawar Zalmi in PSL 11 clash